Pfizer reported strong Phase 3 oncology data for BRAFTOVI, TALZENNA, and LORBRENA, demonstrating improved survival rates across multiple cancers. The company also announced positive mid-stage results for berobenatide, an obesity therapy, with plans for 10 Phase 3 trials to develop the first monthly GLP-1 treatment. Furthermore, Pfizer secured new FDA approvals alongside significant acquisition and collaboration activity involving other industry giants like Johnson & Johnson and Roche.
